Back to List View Graph View

Recombinant zoster vaccine

The recombinant zoster vaccine (RZV), marketed as Shingrix, is a non-live vaccine used to prevent herpes zoster (shingles) in adults.

1 paper landed today · 16 Nov 2026
  • Surveillance of adverse events following immunisation in Australia, 2024. PMID 43035019

Where the papers sit

10 papers from the last 6 months study recombinant zoster vaccine directly

  • Zoster Immunogenicity in Immune Disease

    Robust seroconversion persists in autoimmune rheumatic disease, inflammatory bowel disease, and people living with HIV despite immune-modifying treatment. CD4 T-cell count emerges as an important determinant of immunogenicity in HIV. Safety remains acceptable, including around intravenous cyclophosphamide, while evidence in younger immunocompromised adults supports broader vaccination. Implementation work is beginning to pair these clinical findings with priority-setting for older-adult vaccination.

    4 papers · 40%

  • Zoster Vaccine Safety

    Short-term reactogenicity and feasibility remain the central questions for adults with cancer, liver transplantation, chronic conditions, and older age. Fever and other adverse effects are generally monitored after each dose, with surveys comparing dose 1 and dose 2. Real-world experience supports vaccination during active cancer treatment and after liver transplantation, although population-specific safety data remain limited. Earlier live-vaccine experience provides context, but the recombinant vaccine is the focus of current practice.

    4 papers · 40%

  • Vaccine Safety Surveillance and Uptake

    Routine surveillance is quantifying adverse events after adult vaccination, with fever and incidence rates prominent in national 2024 data. Alongside safety monitoring, current work is identifying which immunocompetent adults initiate and complete the recombinant zoster vaccine series. The emphasis is shifting from isolated event reports toward population-level measurement of exposure, vaccination errors, and coverage. Persistent gaps in completion and interpretation of reported events remain important for program delivery.

    2 papers · 20%

PARADIGM SHIFT

Profound immunosuppression does not broadly prevent recombinant zoster vaccine from producing a strong humoral response

Autoimmune rheumatic disease treated with intravenous cyclophosphamide and people living with HIV stratified by CD4 count were each expected to have impaired vaccine immunogenicity because of cytotoxic treatment or immune deficiency. Instead, cyclophosphamide-treated patients had a 91.9% seroconversion rate, comparable to autoimmune rheumatic disease patients not receiving cyclophosphamide, while all HIV groups—including those with CD4 counts below 300 cells/μL—achieved a 100% humoral vaccine-response rate after dose two; cellular responses were reduced in the low-CD4 group, indicating selective rather than global impairment 42843284Oct 42710800Sep. This shifts the interpretation of immunosuppression from a general barrier to recombinant zoster vaccine response toward a distinction between preserved humoral immunogenicity and potentially weaker cellular immunity.

Papers

The 10 papers from the last 6 months that study recombinant zoster vaccine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Zoster Immunogenicity in Immune Disease (4)
  1. Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide. Vaccine · 7 Oct 2026 PMID 42843284
  2. Brief report: Effectiveness and safety of recombinant zoster vaccine in inflammatory bowel disease patients aged 18 years and older: A matched cohort and self-controlled case series study. Human vaccines & immunotherapeutics · 28 Sept 2026 PMID 42804491
  3. Impact of CD4 T cell counts on the immunogenicity and safety of the recombinant zoster vaccine in people living with HIV. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 8 Sept 2026 PMID 42710800
  4. Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines. Expert review of vaccines · 24 Aug 2026 PMID 42635066
Zoster Vaccine Safety (4)
  1. Adverse events of herpes zoster vaccination among adults in Saudi Arabia: A cross-sectional study. PloS one · 27 Oct 2026 PMID 42945161
  2. Short-Term Adverse Events Following Recombinant Zoster Vaccination in Older Adults in Australia: A Survey Study Comparing Dose 1 and Dose 2 and Influence of Dose Interval. The Medical journal of Australia · 26 Oct 2026 PMID 42928968
  3. Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience. Human vaccines & immunotherapeutics · 30 Jul 2026 PMID 42529910
  4. Outcomes in adult liver transplant patients receiving recombinant herpes zoster vaccine. Vaccine · 20 Jun 2026 PMID 42322677
Vaccine Safety Surveillance and Uptake (2)
  1. Surveillance of adverse events following immunisation in Australia, 2024. Communicable diseases intelligence (2018) · 15 Nov 2026 PMID 43035019
  2. Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018-2024. Human vaccines & immunotherapeutics · 16 Jun 2026 PMID 42301805

By study type

Clinical trials (2)
  1. Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide. Vaccine · 7 Oct 2026 PMID 42843284
  2. Impact of CD4 T cell counts on the immunogenicity and safety of the recombinant zoster vaccine in people living with HIV. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 8 Sept 2026 PMID 42710800
Observational studies and case reports (5)
  1. Adverse events of herpes zoster vaccination among adults in Saudi Arabia: A cross-sectional study. PloS one · 27 Oct 2026 PMID 42945161
  2. Brief report: Effectiveness and safety of recombinant zoster vaccine in inflammatory bowel disease patients aged 18 years and older: A matched cohort and self-controlled case series study. Human vaccines & immunotherapeutics · 28 Sept 2026 PMID 42804491
  3. Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience. Human vaccines & immunotherapeutics · 30 Jul 2026 PMID 42529910
  4. Outcomes in adult liver transplant patients receiving recombinant herpes zoster vaccine. Vaccine · 20 Jun 2026 PMID 42322677
  5. Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018-2024. Human vaccines & immunotherapeutics · 16 Jun 2026 PMID 42301805
Human data, design not indexed (3)
  1. Surveillance of adverse events following immunisation in Australia, 2024. Communicable diseases intelligence (2018) · 15 Nov 2026 PMID 43035019
  2. Short-Term Adverse Events Following Recombinant Zoster Vaccination in Older Adults in Australia: A Survey Study Comparing Dose 1 and Dose 2 and Influence of Dose Interval. The Medical journal of Australia · 26 Oct 2026 PMID 42928968
  3. Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines. Expert review of vaccines · 24 Aug 2026 PMID 42635066